Broad neutralization of SARS-related viruses by human monoclonal antibodies-Reference-Cited by-同舟云学术

Broad neutralization of SARS-related viruses by human monoclonal antibodies

Published:2020-08-07 Issue:6504 Volume:369 Page:731-736
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Wec Anna Z.¹^ORCID,Wrapp Daniel²^ORCID,Herbert Andrew S.³^ORCID,Maurer Daniel P.¹,Haslwanter Denise⁴^ORCID,Sakharkar Mrunal¹,Jangra Rohit K.⁴^ORCID,Dieterle M. Eugenia⁴^ORCID,Lilov Asparouh¹^ORCID,Huang Deli⁵^ORCID,Tse Longping V.⁶^ORCID,Johnson Nicole V.²^ORCID,Hsieh Ching-Lin²,Wang Nianshuang²^ORCID,Nett Juergen H.¹^ORCID,Champney Elizabeth¹,Burnina Irina¹,Brown Michael¹^ORCID,Lin Shu¹^ORCID,Sinclair Melanie¹,Johnson Carl¹,Pudi Sarat¹,Bortz Robert⁴^ORCID,Wirchnianski Ariel S.⁴^ORCID,Laudermilch Ethan⁴,Florez Catalina⁴^ORCID,Fels J. Maximilian⁴^ORCID,O’Brien Cecilia M.³^ORCID,Graham Barney S.⁷^ORCID,Nemazee David⁵^ORCID,Burton Dennis R.⁵⁸⁹¹⁰^ORCID,Baric Ralph S.⁶¹¹^ORCID,Voss James E.⁵^ORCID,Chandran Kartik⁴,Dye John M.³^ORCID,McLellan Jason S.²^ORCID,Walker Laura M.¹^ORCID

Affiliation:

1. Adimab LLC, Lebanon, NH 03766, USA.

2. Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.

3. U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.

4. Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10462, USA.

5. Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.

6. Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

7. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

8. IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.

9. Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.

10. Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA 02139, USA.

11. Departments of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Abstract

Seeking broad protection As scientists develop therapeutic antibodies and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the risk of emergent coronaviruses makes it important to also identify broadly protective antibodies. Wec et al. isolated and characterized hundreds of antibodies against the viral spike protein of SARS-CoV-2 from the memory B cells of a survivor of the 2003 outbreak caused by the related coronavirus, SARS-CoV. In both of these viruses, the spike protein facilitated viral entry by binding to the angiotensin-converting enzyme 2 (ACE2) receptor on human cells. The antibodies targeted multiple sites on the spike protein, but of nine antibodies that showed strong cross-neutralization, eight targeted the domain that binds to ACE2. These eight antibodies also neutralized a bat SARS-related virus. Illuminating the epitopes on the viral spike protein that bind cross-neutralizing antibodies could guide the design of broadly protective vaccines. Science , this issue p. 731

Funder

National Institutes of Health

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference26 articles.

1. A new coronavirus associated with human respiratory disease in China

2. Structure, Function, and Evolution of Coronavirus Spike Proteins

3. Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer

4. Structural insights into coronavirus entry

5. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Cited by 518 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pre-existing cross-reactive neutralizing activity against SARS-CoV-2 and seasonal coronaviruses prior to the COVID-19 pandemic (2014-2019) with limited immunity against recent emerging SARS-CoV-2 variants, Vietnam;International Journal of Infectious Diseases;2024-02

2. Development of SARS-CoV-2 entry antivirals;Cell Insight;2024-02

3. Heterologous Sarbecovirus Receptor Binding Domains as Scaffolds for SARS-CoV-2 Receptor Binding Motif Presentation;ACS Infectious Diseases;2024-01-28

4. Cryptic-site-specific antibodies to the SARS-CoV-2 receptor binding domain can retain functional binding affinity to spike variants;Journal of Virology;2023-12-21

5. Broadly neutralizing antibody induction by non-stabilized SARS-CoV-2 Spike mRNA vaccination in nonhuman primates;2023-12-19